Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 29, 2021
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
[ Mon, Mar 29th 2021
] - WOPRAI
Fri, March 26, 2021
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
[ Fri, Mar 26th 2021
] - WOPRAI
Elliot Wilbur Maintained (ADMA) at Buy with Decreased Target to $6 on, Mar 26th, 2021
Elliot Wilbur of Raymond James, Maintained "ADMA Biologics, Inc." (ADMA) at Buy with Decreased Target from $7 to $6 on, Mar 26th, 2021.
Elliot has made no other calls on ADMA in the last 4 months.
There is 1 other peer that has a rating on ADMA. Out of the 1 peers that are also analyzing ADMA, 0 agree with Elliot's Rating of Hold.
This is the rating of the analyst that currently disagrees with Elliot
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $11 on, Monday, January 4th, 2021
